Making surrogate β-cells from mesenchymal stromal cells: Perspectives and future endeavors

Ramesh R. Bhonde, Preethi Sheshadri, Shikha Sharma, Anujith Kumar

Research output: Contribution to journalReview article

40 Citations (Scopus)

Abstract

Generation of surrogate β-cells is the need of the day to compensate the short supply of islets for transplantation to diabetic patients requiring daily shots of insulin. Over the years several sources of stem cells have been claimed to cater to the need of insulin producing cells. These include human embryonic stem cells, induced pluripotent stem cells, human perinatal tissues such as amnion, placenta, umbilical cord and postnatal tissues involving adipose tissue, bone marrow, blood monocytes, cord blood, dental pulp, endometrium, liver, labia minora dermis-derived fibroblasts and pancreas. Despite the availability of such heterogonous sources, there is no substantial breakthrough in selecting and implementing an ideal source for generating large number of stable insulin producing cells. Although the progress in derivation of β-cell like cells from embryonic stem cells has taken a greater leap, their application is limited due to controversy surrounding the destruction of human embryo and immune rejection. Since multipotent mesenchymal stromal cells are free of ethical and immunological complications, they could provide unprecedented opportunity as starting material to derive insulin secreting cells. The main focus of this review is to discuss the merits and demerits of MSCs obtained from human peri- and post-natal tissue sources to yield abundant glucose responsive insulin producing cells as ideal candidates for prospective stem cell therapy to treat diabetes.

Original languageEnglish
Pages (from-to)90-102
Number of pages13
JournalInternational Journal of Biochemistry and Cell Biology
Volume46
Issue number1
DOIs
Publication statusPublished - 01-2014

Fingerprint

Stem cells
Mesenchymal Stromal Cells
Insulin
Tissue
Blood
Stem Cells
Induced Pluripotent Stem Cells
Dental Pulp
Islets of Langerhans Transplantation
Fibroblasts
Medical problems
Amnion
Umbilical Cord
Liver
Insulin-Secreting Cells
Pulp
Dermis
Embryonic Stem Cells
Cell- and Tissue-Based Therapy
Endometrium

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Cell Biology

Cite this

@article{fc799d6366294a01948d4976e967427d,
title = "Making surrogate β-cells from mesenchymal stromal cells: Perspectives and future endeavors",
abstract = "Generation of surrogate β-cells is the need of the day to compensate the short supply of islets for transplantation to diabetic patients requiring daily shots of insulin. Over the years several sources of stem cells have been claimed to cater to the need of insulin producing cells. These include human embryonic stem cells, induced pluripotent stem cells, human perinatal tissues such as amnion, placenta, umbilical cord and postnatal tissues involving adipose tissue, bone marrow, blood monocytes, cord blood, dental pulp, endometrium, liver, labia minora dermis-derived fibroblasts and pancreas. Despite the availability of such heterogonous sources, there is no substantial breakthrough in selecting and implementing an ideal source for generating large number of stable insulin producing cells. Although the progress in derivation of β-cell like cells from embryonic stem cells has taken a greater leap, their application is limited due to controversy surrounding the destruction of human embryo and immune rejection. Since multipotent mesenchymal stromal cells are free of ethical and immunological complications, they could provide unprecedented opportunity as starting material to derive insulin secreting cells. The main focus of this review is to discuss the merits and demerits of MSCs obtained from human peri- and post-natal tissue sources to yield abundant glucose responsive insulin producing cells as ideal candidates for prospective stem cell therapy to treat diabetes.",
author = "Bhonde, {Ramesh R.} and Preethi Sheshadri and Shikha Sharma and Anujith Kumar",
year = "2014",
month = "1",
doi = "10.1016/j.biocel.2013.11.006",
language = "English",
volume = "46",
pages = "90--102",
journal = "International Journal of Biochemistry and Cell Biology",
issn = "1357-2725",
publisher = "Elsevier Limited",
number = "1",

}

Making surrogate β-cells from mesenchymal stromal cells : Perspectives and future endeavors. / Bhonde, Ramesh R.; Sheshadri, Preethi; Sharma, Shikha; Kumar, Anujith.

In: International Journal of Biochemistry and Cell Biology, Vol. 46, No. 1, 01.2014, p. 90-102.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Making surrogate β-cells from mesenchymal stromal cells

T2 - Perspectives and future endeavors

AU - Bhonde, Ramesh R.

AU - Sheshadri, Preethi

AU - Sharma, Shikha

AU - Kumar, Anujith

PY - 2014/1

Y1 - 2014/1

N2 - Generation of surrogate β-cells is the need of the day to compensate the short supply of islets for transplantation to diabetic patients requiring daily shots of insulin. Over the years several sources of stem cells have been claimed to cater to the need of insulin producing cells. These include human embryonic stem cells, induced pluripotent stem cells, human perinatal tissues such as amnion, placenta, umbilical cord and postnatal tissues involving adipose tissue, bone marrow, blood monocytes, cord blood, dental pulp, endometrium, liver, labia minora dermis-derived fibroblasts and pancreas. Despite the availability of such heterogonous sources, there is no substantial breakthrough in selecting and implementing an ideal source for generating large number of stable insulin producing cells. Although the progress in derivation of β-cell like cells from embryonic stem cells has taken a greater leap, their application is limited due to controversy surrounding the destruction of human embryo and immune rejection. Since multipotent mesenchymal stromal cells are free of ethical and immunological complications, they could provide unprecedented opportunity as starting material to derive insulin secreting cells. The main focus of this review is to discuss the merits and demerits of MSCs obtained from human peri- and post-natal tissue sources to yield abundant glucose responsive insulin producing cells as ideal candidates for prospective stem cell therapy to treat diabetes.

AB - Generation of surrogate β-cells is the need of the day to compensate the short supply of islets for transplantation to diabetic patients requiring daily shots of insulin. Over the years several sources of stem cells have been claimed to cater to the need of insulin producing cells. These include human embryonic stem cells, induced pluripotent stem cells, human perinatal tissues such as amnion, placenta, umbilical cord and postnatal tissues involving adipose tissue, bone marrow, blood monocytes, cord blood, dental pulp, endometrium, liver, labia minora dermis-derived fibroblasts and pancreas. Despite the availability of such heterogonous sources, there is no substantial breakthrough in selecting and implementing an ideal source for generating large number of stable insulin producing cells. Although the progress in derivation of β-cell like cells from embryonic stem cells has taken a greater leap, their application is limited due to controversy surrounding the destruction of human embryo and immune rejection. Since multipotent mesenchymal stromal cells are free of ethical and immunological complications, they could provide unprecedented opportunity as starting material to derive insulin secreting cells. The main focus of this review is to discuss the merits and demerits of MSCs obtained from human peri- and post-natal tissue sources to yield abundant glucose responsive insulin producing cells as ideal candidates for prospective stem cell therapy to treat diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84890028888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890028888&partnerID=8YFLogxK

U2 - 10.1016/j.biocel.2013.11.006

DO - 10.1016/j.biocel.2013.11.006

M3 - Review article

C2 - 24275096

AN - SCOPUS:84890028888

VL - 46

SP - 90

EP - 102

JO - International Journal of Biochemistry and Cell Biology

JF - International Journal of Biochemistry and Cell Biology

SN - 1357-2725

IS - 1

ER -